论文部分内容阅读
目的研究表阿霉素预防浅表性膀胱肿瘤术后复发的可能机制。方法通过细胞培养、免疫组织化学研究不同浓度表阿霉素对膀胱肿瘤EJ细胞株的Ki-67的表达的影响,RT-PCR方法检测术前24 h分别接受生理盐水、阿霉素、表阿霉素膀胱灌注患者膀胱肿瘤组织Fas-mRNA的表达。结果0、30、60、90 mg/L表阿霉素各浓度组Ki-67的阳性率分别为79.60±3.50、60.73±3.31、51.57±3.93、45.83±3.75(P<0.01);表阿霉素较生理盐水可以明显促进肿瘤组织中Fas- mRNA的表达(P<0.01)表阿霉素组和阿霉素组比较差异无统计学意义(P<0.05)。结论表阿霉素可能通过下调Ki-67抑制膀胱肿瘤细胞增殖,促进Fas-mRNA的表达诱导凋亡达到抗肿瘤作用。
Objective To study the possible mechanism of epirubicin in preventing postoperative recurrence of superficial bladder tumor. Methods The effects of different concentrations of epirubicin on the expression of Ki-67 in bladder cancer EJ cell lines were studied by cell culture and immunohistochemistry. The expressions of Ki-67 in bladder tumor EJ cell lines were detected by RT-PCR. Expression of Fas-mRNA in Bladder Tumor Tissue in Patients with Bladder Inoculation of. Results The positive rates of Ki-67 in 0, 30, 60 and 90 mg / L epirubicin groups were 79.60 ± 3.50, 60.73 ± 3.31, 51.57 ± 3.93 and 45.83 ± 3.75 respectively (P <0.01) Compared with normal saline, the expression of Fas-mRNA in tumor tissue was significantly increased (P <0.01). There was no significant difference between epirubicin group and doxorubicin group (P <0.05). Conclusion Epirubicin may have an anti-tumor effect by down-regulating the proliferation of bladder tumor cells and promoting the expression of Fas-mRNA induced by Ki-67.